ISG15 targets glycosylated PD-L1 and promotes its degradation to enhance antitumor immune effects in lung adenocarcinoma

BACKGROUND: Immunocheckpoint inhibitors (ICIs) have been widely used in the clinical treatment of lung cancer. Although clinical studies and trials have shown that patients can benefit significantly after PD-1/PD-L1 blocking therapy, less than 20% of patients can benefit from ICIs therapy due to tum...

Descripción completa

Detalles Bibliográficos
Autores principales: Qu, Tongyuan, Zhang, Wenshuai, Yan, Chenhui, Ren, Danyang, Wang, Yalei, Guo, Yuhong, Guo, Qianru, Wang, Jinpeng, Liu, Liren, Han, Lei, Li, Lingmei, Huang, Qiujuan, Cao, Lu, Ye, Zhaoxiang, Zhang, Bin, Zhao, Qiang, Cao, Wenfeng
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2023
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10204161/
https://www.ncbi.nlm.nih.gov/pubmed/37217923
http://dx.doi.org/10.1186/s12967-023-04135-1

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10204161/
https://www.ncbi.nlm.nih.gov/pubmed/37217923
http://dx.doi.org/10.1186/s12967-023-04135-1

Ejemplares similares